TY - JOUR AU - Khan, Muhammad Ijaz AU - Haider, Ghulam AU - Ahmed, Khalil AU - Shaikh, Shiraz AU - Abbas, Kiran AU - Ahmed, Moiz AU - Sohail, Hamza PY - 2022/06/06 Y2 - 2024/03/29 TI - Combined Military Hospital Quetta/National University of Medical Sciences (NUMS) Pakistan JF - Pakistan Armed Forces Medical Journal JA - PAFMJ VL - 72 IS - SUPPL-2 SE - Original Articles DO - 10.51253/pafmj.v72iSUPPL-2.3996 UR - https://pafmj.org/PAFMJ/article/view/3996 SP - S208-11 AB - <p><strong>Objectives:</strong> To evaluate the tumor grades in different receptors (Estrogen, Progesterone and Her-2/neu) categories and age groups among women with Breast Cancer.</p><p><strong>Study Design:</strong> An observational cross-sectional study.</p><p><strong>Place and Duration of Study:</strong> Oncology department, Jinnah Postgraduate Medical Center, Karachi, from Jul 2017 to Dec 2018.</p><p><strong>Methodology:</strong> Total of 450 patients were enrolled in this study using non-probability consecutive sampling technique. The Receptors Status of Estrogen, Progesterone and Her2/neu was resolved into 4 different categories as i) Triple Positive (ER+PR+HER2+), ii) Triple Negative (ER-PR-HER2-), iii) ER+PR+Her2-, iv) ER–PR-Her2+. Age-wise, patients were divided into 3 groups.</p><p><strong>Results:</strong> The mean age of patients was 46.57 years ± 10.82. No patient was observed with Grade I tumor while 240 with Grade II and 210 with Grade-III. 164/450 patients were observed in the ER+PR+Her2- category. Out of 164, 68.3% were Grade-II and 31.7% were Grade-III (p˂0.001). In Triple-Negative category, 94 patients were observed, 31.90% were Grade-II while 68.10% were Grade-III (p&lt;0.001). The patients, age with tumor Grade also showed statistically significant correlation (p&lt;0.001).</p><p><strong>Conclusion:</strong> This study sheds light on the tumor characteristics of our local population. Majority of our patients had ER+PR+Her2– phenotype/category dominantly having Grade-II tumors followed by Triple Negative typically showing Grade-III. Many of our patients were young (aged less than 36 years) having largely Grade-III tumors while older patients of age above 51 years dominantly showed Grade-II.</p> ER -